Should dual antiplatelet treatment be guided by lipoprotein(a) concentration?

Cardiol J. 2024;31(2):363-364. doi: 10.5603/cj.97979.
No abstract available

Publication types

  • Letter

MeSH terms

  • Biomarkers / blood
  • Dual Anti-Platelet Therapy*
  • Humans
  • Lipoprotein(a)* / blood
  • Platelet Aggregation Inhibitors* / therapeutic use
  • Treatment Outcome

Substances

  • Lipoprotein(a)
  • Platelet Aggregation Inhibitors
  • Biomarkers
  • LPA protein, human